ATE216400T1 - Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle - Google Patents
Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalleInfo
- Publication number
- ATE216400T1 ATE216400T1 AT97942450T AT97942450T ATE216400T1 AT E216400 T1 ATE216400 T1 AT E216400T1 AT 97942450 T AT97942450 T AT 97942450T AT 97942450 T AT97942450 T AT 97942450T AT E216400 T1 ATE216400 T1 AT E216400T1
- Authority
- AT
- Austria
- Prior art keywords
- hepatitis
- complex
- ns4a
- virus
- compositions containing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Metallurgy (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2527496P | 1996-09-12 | 1996-09-12 | |
| US08/731,336 US6153579A (en) | 1996-09-12 | 1996-10-18 | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
| PCT/US1997/016182 WO1998011134A1 (en) | 1996-09-12 | 1997-09-12 | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216400T1 true ATE216400T1 (de) | 2002-05-15 |
Family
ID=26699520
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01101009T ATE244729T1 (de) | 1996-09-12 | 1997-09-12 | Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease |
| AT03015398T ATE346088T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protease-domäne ns3 und ns4a aus dem hepatitis c virus enthalten, und damit bereitgestellte kristalle |
| AT97942450T ATE216400T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01101009T ATE244729T1 (de) | 1996-09-12 | 1997-09-12 | Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease |
| AT03015398T ATE346088T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protease-domäne ns3 und ns4a aus dem hepatitis c virus enthalten, und damit bereitgestellte kristalle |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6153579A (de) |
| EP (1) | EP0935609B1 (de) |
| JP (1) | JP2001501602A (de) |
| AT (3) | ATE244729T1 (de) |
| AU (1) | AU736857B2 (de) |
| CA (1) | CA2264964A1 (de) |
| DE (3) | DE69712085T2 (de) |
| DK (1) | DK0935609T3 (de) |
| ES (2) | ES2202228T3 (de) |
| HK (2) | HK1022700A1 (de) |
| IL (1) | IL128826A0 (de) |
| PT (2) | PT935609E (de) |
| WO (1) | WO1998011134A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129407A0 (en) | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
| CA2359971A1 (en) | 1999-01-08 | 2000-07-13 | Bristol-Myers Squibb Company | Modified forms of hepatitis c virus ns3 protease |
| US6524589B1 (en) * | 1999-04-08 | 2003-02-25 | Schering Corporation | Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same |
| CA2388253A1 (en) | 1999-10-14 | 2001-04-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
| US7491808B2 (en) | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AU2002217838A1 (en) | 2000-11-14 | 2002-05-27 | Bristol-Myers Squibb Company | A human serpin secreted from lymphoid cells LSI-01 |
| WO2002088303A2 (en) | 2001-04-03 | 2002-11-07 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof |
| US20030027315A1 (en) * | 2001-09-24 | 2003-02-06 | Ada Yonath | Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals |
| WO2005000308A2 (en) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
| MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| WO2005042570A1 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Hcv ns3-ns4a protease resistance mutants |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| EP2392589A3 (de) | 2005-11-11 | 2012-06-20 | Vertex Pharmaceuticals Incorporated | Hepatitis-C-Virusvarianten |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| CA2646229A1 (en) * | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| US8440443B1 (en) | 2006-05-16 | 2013-05-14 | Merck Sharp & Dohme Corp. | MEK1 polypeptides |
| WO2008106058A2 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| TW200846343A (en) | 2007-02-27 | 2008-12-01 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
| ATE530546T1 (de) | 2007-08-30 | 2011-11-15 | Vertex Pharma | Kokristalle und pharmazeutische zusammensetzungen damit |
| US8988881B2 (en) * | 2007-12-18 | 2015-03-24 | Sandia Corporation | Heat exchanger device and method for heat removal or transfer |
| US9005417B1 (en) | 2008-10-01 | 2015-04-14 | Sandia Corporation | Devices, systems, and methods for microscale isoelectric fractionation |
| US9795961B1 (en) | 2010-07-08 | 2017-10-24 | National Technology & Engineering Solutions Of Sandia, Llc | Devices, systems, and methods for detecting nucleic acids using sedimentation |
| WO2012118982A2 (en) | 2011-03-02 | 2012-09-07 | Sandia Corporation | Axial flow heat exchanger devices and methods for heat transfer using axial flow devices |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| US5353236A (en) * | 1992-04-23 | 1994-10-04 | The Board Of Trustees Of The Leland Stanford University | High-resolution crystallographic modelling of a macromolecule |
| US5453937A (en) * | 1993-04-28 | 1995-09-26 | Immunex Corporation | Method and system for protein modeling |
| IT1272179B (it) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
-
1996
- 1996-10-18 US US08/731,336 patent/US6153579A/en not_active Expired - Lifetime
-
1997
- 1997-09-12 ES ES01101009T patent/ES2202228T3/es not_active Expired - Lifetime
- 1997-09-12 DE DE69712085T patent/DE69712085T2/de not_active Expired - Lifetime
- 1997-09-12 ES ES97942450T patent/ES2175462T3/es not_active Expired - Lifetime
- 1997-09-12 DE DE69736995T patent/DE69736995T2/de not_active Expired - Lifetime
- 1997-09-12 EP EP97942450A patent/EP0935609B1/de not_active Expired - Lifetime
- 1997-09-12 AT AT01101009T patent/ATE244729T1/de not_active IP Right Cessation
- 1997-09-12 WO PCT/US1997/016182 patent/WO1998011134A1/en active IP Right Grant
- 1997-09-12 CA CA002264964A patent/CA2264964A1/en not_active Abandoned
- 1997-09-12 DE DE69723485T patent/DE69723485T2/de not_active Expired - Lifetime
- 1997-09-12 AT AT03015398T patent/ATE346088T1/de not_active IP Right Cessation
- 1997-09-12 IL IL12882697A patent/IL128826A0/xx unknown
- 1997-09-12 AU AU44145/97A patent/AU736857B2/en not_active Ceased
- 1997-09-12 AT AT97942450T patent/ATE216400T1/de not_active IP Right Cessation
- 1997-09-12 DK DK97942450T patent/DK0935609T3/da active
- 1997-09-12 PT PT97942450T patent/PT935609E/pt unknown
- 1997-09-12 PT PT01101009T patent/PT1118619E/pt unknown
- 1997-09-12 JP JP10513899A patent/JP2001501602A/ja not_active Ceased
-
1999
- 1999-02-25 US US09/257,667 patent/US6303287B1/en not_active Expired - Lifetime
-
2000
- 2000-02-17 HK HK00100944A patent/HK1022700A1/xx not_active IP Right Cessation
- 2000-02-17 HK HK01108615A patent/HK1038573A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0935609T3 (da) | 2002-07-22 |
| AU736857B2 (en) | 2001-08-02 |
| AU4414597A (en) | 1998-04-02 |
| ES2175462T3 (es) | 2002-11-16 |
| IL128826A0 (en) | 2000-01-31 |
| HK1038573A1 (en) | 2002-03-22 |
| DE69736995D1 (de) | 2007-01-04 |
| DE69736995T2 (de) | 2007-09-20 |
| HK1022700A1 (en) | 2000-08-18 |
| CA2264964A1 (en) | 1998-03-19 |
| ATE244729T1 (de) | 2003-07-15 |
| DE69712085T2 (de) | 2002-11-28 |
| DE69723485T2 (de) | 2004-05-27 |
| ATE346088T1 (de) | 2006-12-15 |
| WO1998011134A1 (en) | 1998-03-19 |
| PT935609E (pt) | 2002-09-30 |
| US6303287B1 (en) | 2001-10-16 |
| EP0935609A1 (de) | 1999-08-18 |
| DE69712085D1 (de) | 2002-05-23 |
| US6153579A (en) | 2000-11-28 |
| JP2001501602A (ja) | 2001-02-06 |
| ES2202228T3 (es) | 2004-04-01 |
| EP0935609B1 (de) | 2002-04-17 |
| DE69723485D1 (de) | 2003-08-14 |
| PT1118619E (pt) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE216400T1 (de) | Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle | |
| BG103392A (en) | Serine protease inhibitors, in particular of hepatitis with virus ns3 protease | |
| ATE346035T1 (de) | Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease | |
| ITRM940092A0 (it) | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. | |
| ATE551423T1 (de) | Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika | |
| DE59410380D1 (de) | Endosomolytisch wirksame partikel | |
| DE60144145D1 (de) | Subtilisin-variante | |
| DK0754704T3 (da) | Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus | |
| PT698216E (pt) | Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes | |
| ATE144535T1 (de) | Plättchen blockierende peptide | |
| DE69702705T2 (de) | Kondensierte pyrrolo(2,3-c) carbazole-6-one die die aktivität von gamma interferon potenzieren | |
| DE69928064D1 (de) | Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen | |
| DE69131253D1 (de) | Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein | |
| ATE226591T1 (de) | Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins | |
| FI923020A (fi) | Inte a inte b-sekvenser. | |
| IT1270941B (it) | Peptidi di hcv e loro usi. | |
| SE9604439D0 (sv) | New receptor | |
| RU97111590A (ru) | Средство для лечения хронического простатита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |